Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | CPT2 | P23786 | 2/20 | 0.47 |
| ▸ | CPT1A | P50416 | 2/20 | 0.47 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.47 |
| ▸ | HTR6 | P50406 | 8/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | FABP4 | P15090 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3618419 | 0.92 | CPT2 (0.47) | RECQLCPT2CPT1ACPT1BHTR6 | |
| SCHEMBL3610207 | 0.86 | HTR6 (0.57) | RECQLCPT2CPT1ACPT1BHTR6 | |
| SCHEMBL3615066 | 0.85 | HTR6 (0.57) | RECQLHTR6KMT2AUSP2GAA | |
| SCHEMBL3623733 | 0.83 | HTR6 (0.68) | HTR6 | |
| SCHEMBL3620134 | 0.83 | HTR6 (0.48) | RECQLCPT2CPT1ACPT1BHTR6 | |
| SCHEMBL3620399 | 0.82 | RECQL (0.53) | RECQLCPT2CPT1ACPT1BHTR6 | |
| SCHEMBL3609032 | 0.81 | TSHR (0.46) | RECQLHTR6KMT2AUSP2GAA | |
| SCHEMBL3620928 | 0.81 | HTR6 (0.42) | RECQLCPT2CPT1ACPT1BHTR6 | |
| SCHEMBL3620172 | 0.80 | RECQL (0.51) | RECQLCPT2CPT1ACPT1BHTR6 | |
| SCHEMBL3619876 | 0.79 | HTR6 (0.53) | RECQLHTR6KMT2AUSP2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046741-B1 | INDOLES AS 5-HT6 MODULATORS | PROXIMAGEN LTD (GB) | 2012-10-31 | — | — | EP | claimed |
| US-7812017-B2 | 4-substituted indole and indoline compounds | BIOVITRUM AB (PUBL.) (SE) | 2010-10-12 | — | — | US | claimed |
| EP-2046741-A1 | INDOLES AS 5-HT6 MODULATORS | BIOVITRUM AB (publ) (SE) | 2009-04-15 | — | — | EP | claimed |
| US-20080032968-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2008-02-07 | — | — | US | claimed |
| WO-2008003703-A1 | INDOLES AS 5-HT6 MODULATORS | BIOVITRUM AB (PUBL) (SE) | 2008-01-10 | — | — | WO | claimed |
| EP-2046741-B1 | INDOLES AS 5-HT6 MODULATORS | PROXIMAGEN LTD (GB) | 2012-10-31 | — | — | EP | disclosed |
| US-7812017-B2 | 4-substituted indole and indoline compounds | BIOVITRUM AB (PUBL.) (SE) | 2010-10-12 | — | — | US | disclosed |
| US-7812017-B2 | 4-substituted indole and indoline compounds | BIOVITRUM AB (PUBL.) (SE) | 2010-10-12 | — | — | US | disclosed |
| US-7812017-B2 | 4-substituted indole and indoline compounds | BIOVITRUM AB (PUBL.) (SE) | 2010-10-12 | — | — | US | disclosed |
| US-20080032968-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2008-02-07 | — | — | US | disclosed |
| US-20080032968-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2008-02-07 | — | — | US | disclosed |
| US-20080032968-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2008-02-07 | — | — | US | disclosed |
| WO-2008003703-A1 | INDOLES AS 5-HT6 MODULATORS | BIOVITRUM AB (PUBL) (SE) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032968-A1 | New compounds | HTR6, HTR1B, HTR1A | RECQL 809/4885CPT2 1380/4885CPT1A 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.